Your browser doesn't support javascript.
loading
Genome-wide association study identifies high-impact susceptibility loci for HCC in North America.
Hassan, Manal M; Li, Donghui; Han, Younghun; Byun, Jinyoung; Hatia, Rikita I; Long, Erping; Choi, Jiyeon; Kelley, Robin Kate; Cleary, Sean P; Lok, Anna S; Bracci, Paige; Permuth, Jennifer B; Bucur, Roxana; Yuan, Jian-Min; Singal, Amit G; Jalal, Prasun K; Ghobrial, R Mark; Santella, Regina M; Kono, Yuko; Shah, Dimpy P; Nguyen, Mindie H; Liu, Geoffrey; Parikh, Neehar D; Kim, Richard; Wu, Hui-Chen; El-Serag, Hashem; Chang, Ping; Li, Yanan; Chun, Yun Shin; Lee, Sunyoung S; Gu, Jian; Hawk, Ernest; Sun, Ryan; Huff, Chad; Rashid, Asif; Amin, Hesham M; Beretta, Laura; Wolff, Robert A; Antwi, Samuel O; Patt, Yehuda; Hwang, Lu-Yu; Klein, Alison P; Zhang, Karen; Schmidt, Mikayla A; White, Donna L; Goss, John A; Khaderi, Saira A; Marrero, Jorge A; Cigarroa, Francisco G; Shah, Pankil K.
Afiliación
  • Hassan MM; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Li D; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Han Y; Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas, USA.
  • Byun J; Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas, USA.
  • Hatia RI; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Long E; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Choi J; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Kelley RK; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.
  • Cleary SP; Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, Minnesota, USA.
  • Lok AS; Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Bracci P; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
  • Permuth JB; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
  • Bucur R; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida, USA.
  • Yuan JM; Princess Margaret Cancer Center and Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.
  • Singal AG; Cancer Epidemiology and Prevention Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Jalal PK; Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Ghobrial RM; Division of Digestive and Liver Diseases, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Santella RM; Department of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, Texas, USA.
  • Kono Y; J.C. Walter Jr. Transplant Center, Houston Methodist Hospital, Houston, Texas, USA.
  • Shah DP; Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York City, New York, USA.
  • Nguyen MH; Division of Gastroenterology and Hepatology, University of California San Diego, San Diego, California, USA.
  • Liu G; Mays Cancer Center, The University of Texas Health Science Center San Antonio MD Anderson, San Antonio, Texas, USA.
  • Parikh ND; Division of Gastroenterology and Hepatology, Department of Epidemiology and Population Health, Stanford University Medical Center, Palo Alto, California, USA.
  • Kim R; Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
  • Wu HC; Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • El-Serag H; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
  • Chang P; Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York City, New York, USA.
  • Li Y; Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
  • Chun YS; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Lee SS; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Gu J; Division of Surgery, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Hawk E; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Sun R; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Huff C; Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Rashid A; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Amin HM; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Beretta L; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Wolff RA; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Antwi SO; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Patt Y; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Hwang LY; Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, Florida, USA.
  • Klein AP; Division of Hematology/Oncology, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.
  • Zhang K; Department of Epidemiology, Human Genetics, and Environment Science, The University of Texas Health Science Center at Houston, Houston, Texas, USA.
  • Schmidt MA; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA.
  • White DL; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.
  • Goss JA; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
  • Khaderi SA; Sections of Gastroenterology and Hepatology and Health Services Research, Baylor College of Medicine, Houston, Texas, USA.
  • Marrero JA; Division of Abdominal Transplantation, Michael E. DeBakey School of Medicine, Baylor College of Medicine, Houston, Texas, USA.
  • Cigarroa FG; Division of Abdominal Transplantation, Baylor College of Medicine, Houston, Texas, USA.
  • Shah PK; Division of Digestive and Liver Diseases, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Hepatology ; 80(1): 87-101, 2024 Jul 01.
Article en En | MEDLINE | ID: mdl-38381705
ABSTRACT
BACKGROUND AND

AIMS:

Despite the substantial impact of environmental factors, individuals with a family history of liver cancer have an increased risk for HCC. However, genetic factors have not been studied systematically by genome-wide approaches in large numbers of individuals from European descent populations (EDP). APPROACH AND

RESULTS:

We conducted a 2-stage genome-wide association study (GWAS) on HCC not affected by HBV infections. A total of 1872 HCC cases and 2907 controls were included in the discovery stage, and 1200 HCC cases and 1832 controls in the validation. We analyzed the discovery and validation samples separately and then conducted a meta-analysis. All analyses were conducted in the presence and absence of HCV. The liability-scale heritability was 24.4% for overall HCC. Five regions with significant ORs (95% CI) were identified for nonviral HCC 3p22.1, MOBP , rs9842969, (0.51, [0.40-0.65]); 5p15.33, TERT , rs2242652, (0.70, (0.62-0.79]); 19q13.11, TM6SF2 , rs58542926, (1.49, [1.29-1.72]); 19p13.11 MAU2 , rs58489806, (1.53, (1.33-1.75]); and 22q13.31, PNPLA3 , rs738409, (1.66, [1.51-1.83]). One region was identified for HCV-induced HCC 6p21.31, human leukocyte antigen DQ beta 1, rs9275224, (0.79, [0.74-0.84]). A combination of homozygous variants of PNPLA3 and TERT showing a 6.5-fold higher risk for nonviral-related HCC compared to individuals lacking these genotypes. This observation suggests that gene-gene interactions may identify individuals at elevated risk for developing HCC.

CONCLUSIONS:

Our GWAS highlights novel genetic susceptibility of nonviral HCC among European descent populations from North America with substantial heritability. Selected genetic influences were observed for HCV-positive HCC. Our findings indicate the importance of genetic susceptibility to HCC development.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Predisposición Genética a la Enfermedad / Estudio de Asociación del Genoma Completo / Neoplasias Hepáticas Límite: Aged / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Hepatology Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Predisposición Genética a la Enfermedad / Estudio de Asociación del Genoma Completo / Neoplasias Hepáticas Límite: Aged / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Hepatology Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos